Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clostridium butyricum M588- Miyarisan Pharmaceutical

Next Previous
Drug Profile

Clostridium butyricum M588- Miyarisan Pharmaceutical

Alternative Names: Clostridium butyricum Miyairi 588 strain; C. butyricum CBM 588 Probiotic Strain; C. butyricum MIYAIRI Strain; C. butyricum Strain MIYAIRI 588; CBM-588; Cdactin-O; CM588; Miya-BM; MIYAIRI 588 Strain of C. butyricum; MO-03 1

Latest Information Update: 08 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Miyarisan Pharmaceutical
  • Developer Miyarisan Pharmaceutical; Osel Inc
  • Class Antidiarrhoeals; Antineoplastics; Probiotics
  • Mechanism of Action Gastrointestinal microbiome modulators; Neutrophil stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diarrhoea
  • Phase I Renal cancer; Renal cell carcinoma

Most Recent Events

  • 06 May 2026 Osel and Miyarisan Pharmaceuticals plans a phase II trial for Triple negative breast cancer (Combination therapy, Neoadjuvant therapy) in USA (PO, Capsule) in September 2026 (NCT07552181)
  • 17 Apr 2026 Pharmacodynamics data from a phase I trials in Renal cell carcinoma presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
  • 03 Mar 2026 Clostridium butyricum M588 is still in phase-I development in Renal-cell-carcinoma(Combination therapy, Late-stage disease, Metastatic disease) in USA (PO) (NCT05122546)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top